DSMB quote is encouraging"The trial clearly showed that the Toraymyxin medical device is safe and, even though statistically significant reduction in 28 day mortality was not achieved with this sample size, the 5% mortality reduction in the per protocol population combined with the other positive benefits observed in treated septic shock patients is encouraging," stated Dr. Bert Spilker, Chairman of the Data Safety Monitoring Board." If you came across this stock for the first time today would you buy it?